MindMed Files 8-K Report
Ticker: DFTX · Form: 8-K · Filed: Jun 20, 2024 · CIK: 1813814
| Field | Detail |
|---|---|
| Company | Mind Medicine (Mindmed) Inc. (DFTX) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, regulatory
TL;DR
MindMed filed an 8-K, likely containing routine updates or exhibit filings.
AI Summary
On June 20, 2024, Mind Medicine (MindMed) Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text.
Why It Matters
This filing indicates ongoing reporting requirements for MindMed Inc. and may contain important updates or disclosures for investors.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing header and does not contain information about significant risks or material events.
Key Numbers
- 001-40360 — Commission File Number (Identifies the company's filing with the SEC.)
- 212-220-6633 — Business Phone (Contact number for the company.)
Key Players & Entities
- Mind Medicine (MindMed) Inc. (company) — Registrant
- June 20, 2024 (date) — Date of earliest event reported
- 001-40360 (company) — Commission File Number
- One World Trade Center Suite 8500 (location) — Principal Executive Offices Address
- New York (location) — City of Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Mind Medicine (MindMed) Inc.?
The filing is for 'Other Events' and 'Financial Statements and Exhibits', indicating it may contain routine disclosures or supplementary information.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated June 20, 2024.
What is Mind Medicine (MindMed) Inc.'s Commission File Number?
The Commission File Number for Mind Medicine (MindMed) Inc. is 001-40360.
Where are Mind Medicine (MindMed) Inc.'s principal executive offices located?
The principal executive offices are located at One World Trade Center, Suite 8500, New York, New York, 10007.
Does this filing indicate any specific material event or change for Mind Medicine (MindMed) Inc.?
Based on the provided text, no specific material event is detailed; the filing is categorized under 'Other Events' and 'Financial Statements and Exhibits'.
Filing Stats: 427 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-06-20 08:00:10
Filing Documents
- mnmd-20240620.htm (8-K) — 38KB
- mnmd-ex99_1.htm (EX-99.1) — 18KB
- 0000950170-24-075317.txt ( ) — 179KB
- mnmd-20240620.xsd (EX-101.SCH) — 26KB
- mnmd-20240620_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On June 20, 2024, Mind Medicine (MindMed) Inc. (the "Company") issued a press release announcing the completion of the Company's End-of-Phase 2 meeting with the U.S. Food and Drug Administration. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated June 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mind Medicine (MindMed) Inc. Date: June 20,2024 By: /s/ Robert Barrow Robert Barrow Chief Executive Officer